By Katherine Hamilton
Contineum Therapeutics said its drug designed to treat multiple sclerosis didn't meet its trial endpoints. The stock fell 12%, to $10.75, in after-hours trading Thursday.
Gap Inc. raised its fiscal-year sales outlook after its three main brands logged same-store sales growth. Shares advanced 4.8%, to $24.16, after the bell.
Geospace Technologies said oil volatility and less offshore exploration resulted in an 11% drop in quarterly sales. The stock declined 11%, to $15.35.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
November 20, 2025 18:31 ET (23:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.